Polyrizon Ltd.
Business
Polyrizon Ltd. is a development-stage biotech company that develops intranasal hydrogel medical devices intended to form a thin mucoadhesive shield in the nasal cavity to block viruses and allergens. Its main products are C&C (Capture and Contain) nasal hydrogel sprays designed as physical barriers and T&T (Trap and Target) hydrogel drug-delivery formulations for sustained intranasal API release, plus a licensed SCI-160 pain platform. Key business areas include C&C device candidates (PL-14, PL-15, PL-16), T&T combination-product candidates, and licensing collaborations. The company pursues regulatory clearances in the United States, European Union and other international markets and relies on third‑party manufacturing and distribution channels.
Summary from filing dated 2025-03-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-3.33M |
| Total assets | $21.44M |
| Total liabilities | — |
| Stockholders' equity | $20.99M |
| Operating cash flow | $-4.53M |